AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

B-keto

Claim 1. (Original) A process for preparation of β -keta aliphatic acid ester, which comprises growing a Bacillus sp. IICT 001 in growth medium for a period of at least 3-4 days to obtain broth, extracting the said broth with organic solvent, removing the solvent and purifying the β -keto aliphatic acid ester.

Claim 2. (Original) A process as claimed in claim 1 wherein the growth medium used is selected from the group consisting of nutrient medium and mineral salts medium.

Claim 3. (Original) A process as claimed in claim 1 wherein the growth medium is supplemented with protein and carbon content selected from the group consisting of soyabean meal, corn steep liquor, casein, casein hydrolysate glucose and malt extract.

Claim 4. (Original) A process as claimed in claim 1 wherein the growth of strain is carried out at a temperature range of 20 to 40°C and a pH in the range of 4.5-7.5.

spirloy

Attorney's Docket No. 033432-024

Application No. TBA (Div of 10/098,505)

Page 3

Claim 5. (Original) A process as claimed in claim 1 wherein the solvent for extraction of

broth is a chlorinated organic solvent selected from the group consisting of chloroform,

dichloromethane and dichloroethane.

Claim 6. (Original) A process as claimed in claim 1 wherein the solvent for extraction of

broth is ethyl acetate.

Claim 7. (Original) A process as claimed in claim 1 wherein the solvent for extraction of

broth is a polar solvent selected from the group consisting of methanol, ethanol and a

mixture thereof.

Claim 8. (Original) A process as claimed in claim 1 wherein the chromatographic method

used comprises thin layer chromatography using silica gel as stationary phase and 1:1

methanol CHCl3 as mobile phase, column chromatography, high pressure liquid

chromatography.

Claim 9. (Canceled)

Claim 10. (Canceled)



We claim:

- 1. A process for preparation of β-keto aliphatic acid ester, which comprises growing a Bacillus sp. IICT 001 in growth medium for a period of at least 3-4 days to obtain broth, extracting the said broth with organic solvent, removing the solvent and purifying the β-keto aliphatic acid ester.
- 2. A process as claimed in claim 1 wherein the growth medium used is selected from the group consisting of nutrient medium and mineral salts medium.
- 3. A process as claimed in claim 1 wherein the growth medium is supplemented with protein and carbon content selected from the group consisting of soyabean meal, corn steep liquor, casein, casein hydrolysate glucose and malt extract.
- 4. A process as claimed in claim 1 wherein the growth of strain is carried out at a temperature range of 20 to 40°C and a pH in the range of 4.5-7.5.
- 5. A process as claimed in claim 1 wherein the solvent for extraction of broth is a chlorinated organic solvent selected from the group consisting of chloroform, dichloromethane and dichloroethane.
- 6. A process as claimed in claim 1 wherein the solvent for extraction of broth is ethyl acetate.
- 7. A process as claimed in claim 1 wherein the solvent for extraction of broth is a polar solvent selected from the group consisting of methanol, ethanol and a mixture thereof.
- 8. A process as claimed in claim 1 wherein the chromatographic method used comprises thin layer chromatography using silica gel as stationary phase and 1:1 methanol CHCl₃ as mobile phase, column chromatography, high pressure liquid chromatography.
- 9. An antibiotic compound β-keto aliphatic acid ester isolated from Bacillus sp. IICT 001 and possessing the following spectral properties

UV max (MeoH):

225

¹H NMR CDCI₃(80 M $\underline{\text{H}}_2$): 0.88 t (C $\underline{\text{H}}_3$); 1,25 s, br (C $\underline{\text{H}}_2$)n; 2.16s(COC $\underline{\text{H}}_2$);

3.68 s(COOCH₃) IR. Vmax(CHCI³): cm⁻¹ 1730 (ester), 1670 (Carbonyl).

10. A pharmaceutical composition comprising an effective amount of a β-keto aliphatic acid ester isolated from *Bacillus sp.* IICT 001 and possessing the following spectral properties UV max (MeoH): 225

¹H NMR CDCI₃(80 MH₂): 0.88 t (CH₃); 1.25 s, br (CH₂)n; 2.16s(COCH₂); 3.68 s(COOCH₃) IR. V_{max} (CHCI³): cm⁻¹ 1730 (ester), 1670 (Carbonyl) in admixture with a therapeutically acceptable carrier.